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Abstract
Merkel Cell Carcinoma (MCC) is an aggressive neuroendocrine cancer of the skin. The incidence has been
quadrupled with a 5-year mortality rate of 46%, presently there is no cure for metastatic disease. Despite the
contribution of Merkel cell polyomavirus, the molecular evens of MCC carcinogenesis are poorly de¿ned. To better
understand MCC carcinogensis, we have performed the ¿rst quantitative proteomic comparison of formalin-¿xed,
paraf¿n-embedded (FFPE) MCC tissues using another neuroendocrine tumor (carcinoid tumor of the lung) as
controls. Bioinformatic analysis of the proteomic data has revealed that MCCs carry distinct protein expression
patterns. Further analysis of signi¿cantly over-expressed proteins suggested the involvement of MAPK, PI3K/Akt/
mTOR, wnt, and apoptosis signaling pathways. Our previous study and that from others have shown mTOR activation
in MCCs. Therefore, we have focused on two downstream molecules of the mTOR pathway, lactate dehydrogenase
B (LDHB) and heterogeneous ribonucleoprotein F (hnRNPF). We con¿rm over-expression of LDHB and hnRNPF in
two primary human MCC cell lines, 16 fresh tumors, and in the majority of 80 tissue microarray samples. Moreover,
mTOR inhibition suppresses LDHB and hnRNPF expression in MCC cells. The results of the current study provide
insight into MCC carcinogenesis and provide rationale for mTOR inhibition in pre-clinical studies.

Keywords: Merkel cell carcinoma; PI3K/mTOR pathway; Liquid
tissue platform

Introduction
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine
cancer of the skin with a quadrupled incidence in the past 15 years.
e mortality rate is 46%, exceeding that of melanoma, and there is
presently no cure. Moreover, its incidence is approximately 11-fold
in AIDS patients and 5-fold in organ transplant patients. In addition
to skin cancers, patients with MCC have increased risk for multiple
myeloma, non-Hodgkin’s lymphoma, and in particular chronic
lymphocytic leukemia. Although chronic sun exposure, polyomavirus
and immunosuppression have been implicated in the tumor
development [1-4], our understanding of the cellular and molecular
mechanisms of MCC carcinogenesis and metastasis remains largely
unknown.
Interrogation of MCC tumors of mutation of both tumor
suppressor genes and oncogenes, such as p53, PTEN, Ras, B-RAF, c-kit,
β-catenin, which are frequently involved in human cancers, have failed
to reveal a signi cant role in MCC [5]. However, loss of the pRb1 gene
region and ampli cation of the L-Myc gene region have been found
at a signi cant rate (26% and 31% of tumors, respectively) and have
been postulated to have a functional role in tumor development [6]. In
search of receptor tyrosine kinase (RTK) involvement in MCC (and a
rationale for the use of targeted therapies), studies have found variable
expression of c-kit, VEGFs, PDGFα and PDGFβ in MCCs compared to
normal skin [7,8]. Moreover, study has shown MAP kinase pathway
is silent (as demonstrated by lack of pathway activation and no ERK
phosphorylation) in the majority of MCCs examined [9]. Furthermore,
a separate study using a MCC cell line demonstrates that inactivation
of MAP kinase pathway is important in MCC carcinogenesis [10].
Additionally, one study using tissue microarray shows expressions

of MMPs, VEGFs, P38, stromal NF-Kappa B and synaptophysin are
associated with aggressive behavior [11].
Genomic studies such as chromosomal comparative genomic
hybridization (CGH) have been employed to examine copy number
alterations in MCCs. Chromosomes 1, 3q, 5p and 6 are frequently
increased in copy number whereas chromosomes 3p, 4, 5q, 7, 10 and
13 are frequently lost [12]. Additionally, transcriptome pro ling has
identi ed a subgroup of MCCs with intratumoral CD8 positive T
cell in ltration thatis associated with better prognosis [13]. Although
the causes of cancer lie in mutations or epigenetic changes at the
chromosomal level, their molecular manifestation is correlated to the
dysfunction of biochemical pathways at the protein level. In addition, the
plasticity of mRNAs raises questions whether RNA expression changes
are translated to those of proteins that are central to carcinogenesis.
erefore, de ning the protein pro les and dysregulation of their
expression level in cancer is critical.
Global proteomic analysis has become a promising strategy to
identify potential biomarkers in various cancer subtypes. However,
one of the obstacles of human tissue research for proteomic study is the
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preferential use of snap frozen fresh tissues that are restricted in human
skin biopsy samples. e Liquid Tissue platform, a novel technology
for protein extraction from formalin- xed, para n-embedded (FFPE)
tissue blocks, permits facile global proteomic analysis of archival
specimens by mass spectrometry to identify novel or critical proteins
from human archival tissues. Moreover, no proteomic study has been
performed in MCC and the proteins essential for the transformation of
MCC have not been identi ed.
In this study, we used a quantitative proteomic platform to
assessprotein expression in FFPE MCC tumors. Because of the
neuroendocrine nature of MCC, we chose another neuroendocrine
tumor, carcinoid tumors of the lung, as the control. We identi ed
signi cantly over-expressed proteins in MCC. Interestingly, further
pathway analysis of our protein data implicated the involvement of
MAPK, PI3K/Akt/mTOR, wnt, and apoptosis signaling pathways.
As shown previously mTOR pathway is activated in MCCs [14,15],
therefore we selected this pathway for further investigation. Two
molecules downstream of the mTOR pathway, lactate dehydrogenase
B (LDHB) and heterogeneous ribonucleoprotein F (hnRNPF), were
studied. We rst con rmed the expression of LDHB and hnRNPF in
tissue microarray including 80 MCC samples and two primary human
MCC cell lines established in the lab. Moreover, mTOR inhibition
suppressed both LDHB and hnRNPF expression in MCC cells. e
results of the current study will provide insight into our understanding
of MCC carcinogenesis and has translational potential for clinical
practice by facilitating the identi cation of useful biomarkers for early
diagnosis and prognosis as well as identifying novel therapeutic targets
of MCC.

Materials and Methods
Sample selection and tissue microarray
In accordance with institutional approvals for human study
protocol, a total of 10 MCCs and 5 carcinoid tumor of the lung
formalin xed para n embedded (FFPE) tissue blocks were selected
for proteomic study. Tissue microarray (TMA) included80 FFPE
MCC tissue blocks and were prepared as previously described [15].
Brie y, for each case a representative area from the tumor was carefully
selected from a hematoxylin-eosin stained section of a MCC tissue
block. Core cylinders (0.6 mm) were punched from each FFPE tumor
and deposited into a recipient para n block using the MTA-I manual
tissue arrayer (Beecher). Five-micrometer sections of the resulting
TMA blocks were made and used for immunohistochemistry.

Immunohistochemistry
Immunohistochemistry was performed on 5 µm sections of
TMA slides. e slides were depara nized and rehydrated in water.
Antigen retrieval was performed by microwaving in 0.01 M sodium
citrate for 20 min. Tissue peroxide activity was blocked with 1%
hydrogen peroxide at room temperature (RT) for one hour followed
by washing twice in PBS.
e sections were further blocked with
normal goat serum at RT for one hour followed by incubation with
LDHB (Lifespan Biosciences) and hnRNPF (Abcam) at 4°C overnight,
respectively. Secondary goat anti-rabbit antibody (1:200) was applied
to the slides for one hour at RT before developing in HRP detection
system and freshly prepared diaminobenzidine as the chromogen
(brown). Sections were counterstained with hematoxylin. Staining was
manually scored. Immunostained slides were viewed on an Olympus
BX51 Research System Microscope by 10x and 20x UPlanApo air

objective lenses (Olympus America). Images were photographed using
a high-resolution interline CCD camera (CoolSNAPcf, Photometrics),
and acquired with automated microscopy acquisition so ware
(MetaMorph version 7.7, Molecular Devices).

Cell lines and reagents
In accordance with institutional approvals for human study
protocol, we have established two primary human Merkel cell
carcinoma cell lines (MCC-2 and MCC-3) from lymph node metastases
of two patients [15]. Both cell lines were maintained in RPMI medium
with 10% Fetal Bovine Serum (FBS), penicillin and streptomycin. Fresh
medium was added every other day and cultures were split 1:2 weekly
following complete removal of the medium. mTOR inhibitors Ku0063784 and PP242 were obtained from Sigma Aldrich.

Immunoblotting
Membranes were blotted with antibodies directed against (LDHB
and hnRNPF). Bound antibodies were detected with horseradish
peroxidase-linked antibody against mouse or antibody against rabbit
(IgG; Amersham), followed by ECL detection (Amersherm).

Gene expression analysis
RNAs were isolated from MCC fresh tissues and control carcinoid
tumors of the lung with RNeasy kit (Qiagen). cDNA was generated
from mRNA using a Reverse Transcription Kit (Applied Biosystems).
SYBR Green-based quantitative reverse transcription-PCR (qRT-PCR)
was performed with a StepOnePlus Real-Time PCR System (Applied
Biosystems). Triplicate runs of each sample were normalized to MRPS2
mRNA to determine relative expression.

Quantitative proteomics
A single 10 µm tissue section was made and mounted on Director
slide (Expression Pathology, Gaithersburg, MD), and heated for 1
hour at 60°C. Para n was removed with xylene followed by tissue
rehydration through a series of graded ethanol solutions and distilled
water. Approximately 30,000 tumor cells were procured by needle
microdissection.
e Liquid Tissue MS Protein Prep Kit (Expression Pathology)
was used to reverse cross-linking and the extracted proteins were
analyzed by Coomassie/sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Each SDS-PAGE gel lane was cut into 3
mm slices and subjected to in-gel trypsin digestion as follows. Proteincontaining gel slices were destained in 50% methanol (Fisher), 100 mM
ammonium bicarbonate (Sigma-Aldrich), followed by reduction in
10 mM Tris [2-carboxyethyl]phosphine (Pierce) and alkylation in 50
mM iodoacetamide (Sigma-Aldrich). Gel slices were then dehydrated
in acetonitrile (Fisher), followed by addition of 100 ng porcine trypsin
(Promega) in 100 mM ammonium bicarbonate (Sigma-Aldrich)
and incubation at 37°C for 12-16 hours. Peptide products were then
acidi ed in 0.1% formic acid (Fluka). Tryptic peptides were separated
by reverse phase Jupiter Proteo resin (Phenomenex) on a 100×0.1 mm
column using a nanoLC 2D system (Eksigent). Peptides were eluted
using a 30 min gradient from 98:2 to 40:60 bu er A:B ratio. [Bu er
A=0.1% formic acid, 0.05% acetonitrile; bu er B=0.1% formic acid,
75% acetonitrile.] Eluted peptides were ionized by electrospray (2.0
kV) followed by MS/MS analysis using collision induced dissociation
on an LTQ XL mass spectrometer ( ermo). MS data were acquired
over a range of 375 to 1500 m/z. MS/MS data were acquired for the top
7 peaks from each MS scan. Proteins were identi ed by database search
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using Mascot (Matrix Science).Tandem mass spectrometric data was
searched with an in-house version of Mascot against the UniprotKB/
SwissProt Homo sapiens protein database for protein identi cation.
In order to quantify the relative protein level in these samples, we
used a mass spectrometric technique called spectral counting using
parameters as detailed by Byrum et al. [16]. A spectral count is the
number of tandem mass spectra assigned to a given protein and re ects
the abundance of the protein. We then calculated a normalized spectral
abundance factor (NASF), which re ects the amount of a given protein
relative to the total proteins identi ed in the gel lane [17,18]. e NASF
was calculated as follows:
SpC
(
)k
( NASF ) k = N L
SpC
(
)i
∑
L
i =1
e variables are de ned as follows: k is a given protein, SpC are the
spectral counts, L is the length of the protein, and N is the sum of all
proteins identi ed in the gel lane. For a given protein, this reveals what
fraction of the total proteins identi ed in the gel lane is the particular
protein. e data distribution of the normalized spectral counts showed
a bimodal distribution and therefore, the Wilcoxon rank sum test with
the t-approximation was used to identify signi cantly di erentiating
proteins between the two groups. e enrichment level for each protein
was identi ed by calculating the fold change (CK/Lung) using the
average ln (NSAF) values for each protein. Fold change was calculated
by taking the anti-log of (ln(NSAF)avg CK–ln(NSAF)avg Lung). Proteins
with a p-value<0.05 and a FC>1.5 were considered signi cant.

Pathway analysis using DAVID uncovered several signaling
pathways that are potentially important for MCC pathogenesis (Table
1). Proteins identi ed are also known to play a role in multiple diseases
such as Parkinson’s disease, Huntingtons disease, systemic lupus
erythematosus, and areassociated with normal metabolic activities
such as the citrate cycle, glycolysis/gluconeogenesis, and metabolism
of amino acids. Of particular interest are proteins involved in focal
adhesion, epithelial cell signaling, and the spliceosome. A manual
literature search using the signi cantly di erentiatingproteins in
PubTatorhas revealed proteins involved in MAPK, PI3K/Akt/mTOR,
wnt, and apoptosis signaling pathways (Table 2). Interestingly, we have
uncovered several proteins involved in the MAPK pathway, which
has previously been indicated as silent in MCCs [10]. e PI3K/AKT/
mTOR signaling cascade is commonly dysregulated in human cancers
[25-27]. Moreover, we have found mTOR activation is common
in MCCs [15]. erefore, we have selected two proteins, LDHB and
hnRNPF, which are found to be signi cantly up-regulated in MCCs
and are downstream e ectors of mTOR pathways, for further study
and validation.

Expressions of LDHB and hnRNP are up-regulatedin fresh
tumor tissues and primary human MCC cell lines at the
mRNA level
e mammalian target of rapamycin (mTOR) pathway is a master
regulator of protein synthesis and frequently activated in human
cancers [28]. mTOR resides in two complexes, mTOR complex1

e most important signaling pathways were identi ed using the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) v6.7 [19]. Signi cantly di erentiating proteins, not identi ed
in signaling pathways by DAVID, were searched in the literature using
a web-based search tool, PubTator, for involvement in known pathways
using the protein’s gene symbol plus the keyword “pathway” [20,21].

Results
Distinct protein expression pro les in Merkel cell carcinoma
e proteome from 10 metastatic MCC tumors and 5 carcinoid
tumor of the lung were measured in this study. As shown in Figure 1,
each protein sample was resolved by Coomassie/SDS-PAGE followed
by in-gel trypsin digestion and LC-MS/MS. A total of 1356 proteins
were identi ed for all samples at a 1% false discovery rate using a decoy
database. To determine whether a protein was di erentially expressed
between MCC and the carcinoid tumors of the lung, a label-free
approach based on spectral counting was used [18,22-24]. e relative
abundance of each protein was normalized using the normalized
spectral abundance factor (NSAF) and the frequency distribution of
ln(NSAF) values showed a bimodal distribution. ere were a total
of 432 proteins identi ed with a fold change>1.5 in MCCs compared
to the carcinoid tumor of lung. A Wilcoxon rank sum test with
t-approximation identi ed 375 signi cantly di erentiating proteins
between MCCs and carcinoid tumor of the lung with a p-value<0.05.
A heat map was generated using Hierarchical Clustering Explorer
(HCE version 3.0) with all 375 signi cant proteins, the average linkage
method, and Euclidean distance metric. e MCC and carcinoid tumor
of the lung patient samples were clearly separated into two separate
clusters based on these signi cantly di erentiating proteins. Up- or
down-regulated proteins in MCCs are indicated in red and green,
respectively (Figure 2).

Figure 1: Representative gel lanes for quantitative mass spectrometric
analysis of MCC and carcinoid tumor of the lung from formalin-¿xed
paraf¿n-embedded (FFPE) tissues. Proteins were extracted from 10 MCC
FFPE tissues and 5 carcinoid tumors of the lung FFPE tissues. The samples
were equally loaded and resolved by sodium dodecyl sulfate polyacrylamid
gel electrophoresis (SDS-PAGE)/Coomassie. Each gel lane was sliced into 23
bands, subjected to trypsin digestion and peptides were analyzed by liquid
chromatography-mass spectrometry (LC-MS)/MS with a Thermo LTQ-XL mass
spectrometer. Proteins were identi¿ed by a Mascot database search (95%
con¿dence threshold). One gel lane from each group is shown.
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(mTORC1) and mTOR complex (mTORC2), which execute distinct
cellular tasks. Rapamycin and its analogues are allosteric inhibitors
via mTORC1 inhibition. Underscored by the clinical ine cacy of
allosteric inhibitors, more potent inhibitors of the active site of
mTOR kinase, such as PP242 and Ku-0063794, have been developed.
e major regulators of protein synthesis downstream of mTOR are
eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1
(4E-BP1) and S6 kinase (S6K). Similar to 4E-BP1, dysregulation of S6K
signaling has been linked to human pathologies, including cancer and
diabetes. ere are two isoforms, S6K1 and S6K2, which are found to
be up-regulated at both the RNA and protein levels in several types of
human cancers. In contrast to S6K1, the S6K2 is specially associated
with a number of RNA-binding proteins, including heterogeneous
ribonucleoproteins (hnRNPs). Moreover, hnRNPF has been shown to
regulate cell proliferation via S6K2 in breast cancer cell lines [29].
In tumor cells, glucose is preferentially converted into lactic acid
through aerobic glycolysis, which is known as the “Warburg e ect”.
LDH is the key glycolytic enzyme catalyzing the formation of lactic acid
from pyruvate, is o en activated in cancers [30]. LDHB is critical for
hyperactive mTOR mediated tumorigenesis.
Taking advantage of two primary human MCC cells lines
established in our laboratory as well as fresh MCC tumor samples, we
measured the expression of LDHB and hnRNPF at the mRNA level.
mRNAs were extracted from fresh tumors, MCC-2 and MCC-3 cell
lines followed by qPCR. cDNA from a fresh carcinoid tumor of the
lung was used as a control. Compared to the carcinoid tumor of the
lung, signi cantly increased expression of LDHB and hnRNPF was
found in 16/16 and 11/16 fresh MCC tumors, respectively (Figure 3).
Similarly, both MCC-2 and MCC-3 cell lines demonstrated increased
expression of both mRNAs. erefore, we have demonstrated overexpression of LDHB and hnRNPF at the mRNA level in MCCs, which
con rms our proteomic results.

LDHB and hnRNPF are over-expressed in human MCC tissue
microarray samples
To further con rm our observations, we examined 80 MCC
tumor samples using TMA. As shown in Figure 4, over-expression as
indicated by positive nuclear staining of hnRNPF (brown) and positive
cytoplasmic staining of LDHB (brown), respectively. Over-expression
of LDHB and hnRNPF was detected in the majority of MCCs. Seventyfour out of eighty (92.5%) and seventy-eight out of eighty (97.5%)
MCC samples were positive for LDHB and hnRNPF, respectively. us,
we have shown up-regulation of LDHB and hnRNPF in MCCs at the
protein level, which again con rms our proteomic studies.

mTOR inhibitions suppresses LDHB and
expressions in both MCC-2 and MCC-3 cells

Figure 2: Hierarchical clustered heat map of the 375 signi¿cant proteins
differentially expressed between MCC and carcinoid tumors of the lung
as determined by Wilcoxon rank sum test (p < 0.05). LDHB and hnRNPF
proteins were upregulated in MCC tumors compared to carcinoid tumors of the
lung and were selected for further validation.

hnRNPF

To evaluate whether LDHB and hnRNPF are downstream e ectors
of the mTOR pathway, MCC-2 and MCC-3 cellswere treated with
the active site ATP mTOR inhibitors Ku-0063784 and PP242 for 24
hours, respectively. Cell lysates were subjected to LDHB and hnRNPF
immunoblotting. mRNAs were extracted from MCC-2 and MCC-3
cells treated with mTOR inhibitors followed by qPCR analysis of LDHB
and hnRNPF. Consistent with previous ndings in other types of
human cancer [29,30], reduced LDHB and hnRNPF expressions were
observedboth at the mRNA and protein levels in MCC-2 and MCC-3
cells following mTOR pathway inhibition, indicating that LDHB and
hnRNPF are downstream e ectors of mTOR pathway (Figure 5).
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Pathway

Oxidative phosphorylation

Parkinson’s disease

Count

24

18

P-value

Proteins

Fold Enrichment

Bonferroni

Benjamini

FDR

8.09E-11

UQCRC1, ATP6AP1, ATP6V1G1, COX5A,
UQCRFS1, COX5B, UQCRQ, UQCRFSL1,
NDUFS7, NDUFS6, NDUFS4, ATP5L,
ATP6V0D1, ATP5I, NDUFS1, NDUFA5,
NDUFA2, ATP5F1, ATP6V1H, ATP6V1F,
COX6C, NDUFV1, ATP6V1E1, ATP6V0A1,
UQCRB

5.18657

1.00E-08

1.00E-08

9.34E-08

2.00E-06

NDUFA5, NDUFA2, UQCRC1, SLC25A4,
ATP5F1, COX5A, VDAC2, UQCRFS1,
UQCRQ, COX5B, UQCRFSL1, COX6C,
VDAC1, NDUFS7, NDUFS6, NDUFS4,
NDUFV1, NDUFS1, UQCRB

3.950708

2.48E-04

1.24E-04

0.00231

2.96547

0.006812

0.002276

0.063633

Huntington’s disease

19

5.51E-05

NDUFA5, NDUFA2, UQCRC1, SLC25A4,
ATP5F1, COX5A, VDAC2, UQCRFS1,
UQCRQ, COX5B, UQCRFSL1, COX6C,
VDAC1, DCTN2, NDUFS7, NDUFS6,
NDUFS4, NDUFV1, NDUFS1, UQCRB

Systemic lupus erythematosus

13

1.68E-04

HLA-DRB1, ACTN4, C4A, SNRPD3, ACTN1,
HIST1H2BO, TROVE2, HIST1H2BL,
3.689101
HIST1H3A, H2AFY2, SNRPB, H2AFY,
H3F3A

0.020611

0.005193

0.193756

Vibrio cholerae infection

9

6.99E-04

ACTG1, ACTB, ATP6AP1, ATP6V1E1,
ATP6V1H, ATP6V0A1, ATP6V1G1,
ATP6V0D1, ATP6V1F

4.515095

0.083065

0.017194

0.804307

Spliceosome

13

0.001537

SNRPA1, SNRPD3, SNRPD2, HNRNPA1,
NAA38, SF3B3, HNRNPU, RBM8A, PCBP1, 2.898579
SNRPB, MAGOHB, SNRNP70, SNRPE

0.173673

0.031294

1.760801

Cardiac muscle contraction

10

0.001584

ATP1B1, ACTC1, UQCRC1, ATP1A1,
UQCRFS1, COX5A, UQCRQ, COX5B,
UQCRFSL1, UQCRB, COX6C

3.601785

0.178439

0.027688

1.81371

Alzheimer’s disease

15

0.001737

NDUFA5, NDUFA2, UQCRC1, ATP5F1,
COX5A, UQCRFS1, COX5B, UQCRQ,
UQCRFSL1, COX6C, NDUFS7, NDUFS6,
NDUFS4, NDUFV1, NDUFS1, UQCRB

2.58533

0.193896

0.026583

1.987221

Table 1: Signaling pathways identi¿ed by DAVID. The list of signi¿cantly differentiating proteins between MCC and carcinoid tumors of the lung was imported into the
DAVID functional annotation web-tool. The proteins identi¿ed in signaling pathways from the KEGG database are listed.

Figure 3: Expression of LDHB and hnRNPF in fresh MCC tumor tissues and two primary human MCC cell lines. cDNAs were extracted from 16 fresh MCC
tumors and 2 primary human MCC cell lines and qRT-PCR analysis of LDHB and hnRNPF mRNA expression was performed. cDNA from a fresh carcinoid tumor
of the lung was used as a control. Triplicate runs of each sample were normalized to MRPS2 mRNA to determine relative expression (means ± SEM), (**P < 0.01,
***P< 0.001).
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Protein Name

Gene symbol

PMID

Basal cell adhesion molecule OS

BCAM

23160466

Peroxiredoxin-1

PRDX1

19941984

20188343

N(G),N(G)-dimethylarginine
dimethylaminohydrolase1

DDAH1

21212404

GNB2L1

22240482

Proliferating cell nuclear antigen

PCNA

23298485

COL1A2

22131293

Filamin-A

FLNA

22203038

AKR1C3

18508192

Gene symbol

PMID

Fascin

FSCN1

20502940

Galectin-7

LGALS7

21289092

LUM

23154825

SERPINH1

Guanine nucleotide-binding protein
subunit beta-2-like 1
Collagen alpha-2(I) chain

MAPK (pERK) Pathway

Lumican
Serpin H1

Protein Name
PI3K/Akt/mTOR Pathway

UDP-glucose 6-dehydrogenase

UGDH

14505572

Metalloproteinase inhibitor 1

TIMP1

23555182

Aldo-keto reductase family 1 member
C3 OS

CPE

22824791

ATP-citrate synthase OS

HDGFRP3

22490522

Stathmin

Ras-related protein Rab-

RAB7A

19372461

ATP synthase subunit e, mitochondrial
OS

ATP5I

Carboxypeptidase E OS
Hepatoma-derived growth factor-related
protein 3

ACLY

18922930

STMN1

21683992

Serum amyloid P-component

APCS

23182717

11939412

UDP-glucose 6-dehydrogenase

UGDH

14505572

CHGA

10197763

Keratin, type II cytoskeletal 8

KRT8

23449973

LGALS3BP

22389450

Peroxiredoxin-6

PRDX6

21346153

Metalloproteinase inhibitor 1

TIMP1

23555182

Stress-70 protein, mitochondrial

HSPA9

12646231

Collagen alpha-1(VI) chain

COL6A1

11279127

Annexin A2 OS

ANXA2

22040021

Collagen alpha-3(VI) chain

COL6A3

11279127

Peroxiredoxin-1

PRDX1

23602274

HNRNPF

RasGAP-like with IQ motifs

IQGAP1

23603816

Heterogeneous nuclear
ribonucleoprotein F

TPP1

22101936

L-lactate dehydrogenase B chain

LDHB

21199794

22203038

Poly [ADP-ribose] polymerase 1

PARP1

17525332

Small nuclear ribonucleoprotein E

SNRPE

23358685

Guanine nucleotide-binding protein
subunit beta-2-like 1

GNB2L1

22240482

CPE

22824791

ATP-dependent RNA helicase DDX3X

DDX3X

23413191

High mobility group protein B2*

HMGB2

19805379

GNB2L1

22240482

Chromogranin-A OS
Galectin-3-binding protein

Tripeptidyl-peptidase 1
Filamin-A

FLNA

Apoptosis

21157483

FACT complex subunit SSRP1

SSRP1

16498457

Apoptosis-inducing factor 1,
mitochondrial OS

AIFM1

16636662

Cytochrome c oxidase subunit 6C

COX6C

22860893

Diablo homolog, mitochondrial

DIABLO

10972280

Eukaryotic translation initiation factor 3
subunit B

EIF3B

22234522

Glutaredoxin-1

GLRX

17185628

Glutathione peroxidase 3

GPX3

22461624

Guanine nucleotide-binding protein
subunit beta-2-like 1

HNRNPU

20101230

Glutathione S-transferase Mu 3

GSTM3

20118494

MTCH2

15899861

PFN1

23331014

Methyl-CpG-binding protein 2

MECP2

23200852

ARHGDIA

19077262

SRI

22052463

Very long chain acyl-CoA
dehydrogenase, mitochondrial

ACADVL

9680378

Polyadenylate-binding protein 2

PABPN1

22519734

Galectin-7

Heterogeneous nuclear
ribonucleoprotein U
Mitochondrial carrier homolog 2
Pro¿lin-1
Rho GDP-dissociation inhibitor 1
Sorcin

LGALS7

21289092

DNA replication licensing factor MCM3

MCM3

10495426

Annexin A2 OS

ANXA2

22040021

Discussion
A hallmark of human cancer is heterogeneity. At the genetic level,
it re ects the complex series of changes resulting in the activation of
oncogenes coupled with inactivation of tumor suppressor genes. At
the patient level, it manifests by disease outcome, response to therapy
and ability to metastasize. At the pathological level, it is observed
where certain histological features are associated with more aggressive
cancers. An ability to model this complexity is crucial to identify
therapeutic targets for cancers evading therapy. However, targeted

Wnt Pathway
Carboxypeptidase E OS

Moesin

MSN

23221384

Ras GTPase-activating protein-binding
protein 1

G3BP1

21652632

Annexin A1 OS

ANXA1

21383699

Table 2: Proteins identi¿ed in PI3K/Akt/mTOR, p38 MAPK, Apoptosis, and
wnt signaling pathways. The protein name, gene symbol, accession number, and
PubMed identi¿er (PMID) for the journal linking the protein to a particular signaling
pathway are listed for each protein.

therapy at the gene level remains a challenge as there is a distinction
between driver mutations that can propel the development of cancer
and driver mutations on which the cancer cell continually depends.
Interrogation of tumors at the genomic and transcriptomic level may
therefore not precisely present the complexity of the tumor itself or
its biologic environment, including uctuating in clonal variation,
changes in in gene expression and host response, and signaling events
that lead to changes at the protein level. Because many drugs act on
protein e ectors, in combination with genomic and transcriptomic
pro ling, proteomic pro ling o ers the promise of additional insights
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Figure 4: hnRNPF and LDHB expression in MCC tissue microarray
samples. (A-D) Representative negative and positive immunohistochemical
staining of hnRNPF (brown nuclear staining) and percentages of negative
samples, and samples with weak, moderate and strong positives. (E-H)
Representative negative and positive immunohistochemical staining of LDHB
(brown cytoplasmic staining) and percentages of negative samples, and
samples with weak, moderate and strong positives.

into cancer status and may be a better approach to identify therapeutic
targets.
Merkel cell carcinoma is a neuroendocrine skin tumor with
aggressive behavior and poor prognosis. Fi y percent of patients are
metastatic upon diagnosis. Despite standard treatment that is surgery
followed by radiation therapy, one third of patients eventuate distant
metastasis. Evidence-based e ective chemotherapy for metastatic
disease has not yet developed. We have taken the approach to
investigate metastatic tissue, with the rationale that the tumor cells
present in lymph node are molecularly programmed to “escape”
surveillance mechanisms and metastasize – the ultimate behavior that
drives disease progression. In this study, taking advantage of the liquid
platform technique using archival tissues to identify molecules that are
integral to speci c signaling pathways known to be important in tumor
biology. We have identi ed increased expression of members of the
RTK/PI3K/Akt/mTOR, wnt and MAPK pathways, which we propose
are important in MCC pathogenesis. In fact, we have con rmed the
overexpression of LDHB and hnRNPF, two downstream mTOR
e ectors in MCCs by qPCR and immunoblotting, supporting the
involvement of this pathway in MCC tumorogenesis.

Figure 5: mTOR inhibition suppresses LDHB and hnRNPF expression in
both MCC-2 and MCC-3 cells. (A) Suppressed LDHB and hnRNPF mRNA
expression in MCC-2 and MCC-3 cells. MCC-2 and MCC-3 cells were treated
with DMSO, Ku-0063794 (5μM) and PP242 (2.5μM) for 24 hours, respectively.
cDNAs were extracted and expression of hnRNPF and LDHB was analyzied
by qPCR. Triplicate runs of each sample were normalized to MRPS2 mRNA
to determine relative expression (means ± SEM), (*P < 0.05, ***P< 0.001).
(B) Suppressed mTOR pathway, LDHB and hnRNPF protein expressions in
MCC-2 and MCC-3 cells by immunoblottings. MCC-2 and MCC-3 cells were
treated with DMSO, Ku-0063794 (5μM) and PP242 (2.5μM) for 24 hours,
respectively. Lysates were prepared and subjected to immunoblotting analysis
with indicated antibodies. β-actin served as proper loading control.

Increased expression of LDHB in MCCs suggests increased tumor
metabolism depending on glycolysis in energy demand and further
implies the idea that MCCs are sensitive to perturbation in the end
stage of glycolysis-lactate production, and thus open a therapeutic
window in the clinics. Moreover, increased expression of hnRNPF is
indicative of additional molecules along mTOR pathway other than
4E-BP1 and S6K1 involved in MCC pathogenesis. Aberrant RTK/
PI3K/Akt/mTOR pathway has a key role in human cancer initiation,
progression, invasion, metastasis and resistance to therapy. Our current
study supports the ndings of two separate independent studies, which
has revealed a dysregulated RTK/PI3K/Akt/mTOR pathway in MCC
[25,26]. Cumulatively, these ndings suggest that inhibitors of this
pathway hold treatment promise in these tumors, either as initial single
agents, or in combination with standard cytotoxic chemotherapy and
radiotherapy.
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